Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents

Iuliana Vaxman, Alissa Visram, Shaji Kumar, Angela Dispenzieri, Francis Buadi, David Dingli, Martha Lacy, Eli Muchtar, Prashant Kapoor, William Hogan, Suzanne Hayman, Nelson Leung, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Tamar Berger, Morie A. Gertz

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma (MM) for over three decades and is generally reserved for patients younger than 65. Herein we report on outcomes of outpatient ASCT in a cohort of patients with MM aged ≥75 years. Between October 2005 and August 2020, 50 patients aged ≥75 years, received an ASCT at Mayo Clinic, Rochester. Median time from diagnosis to ASCT was 6.85 months (IQR 5.2–10.52) and 50%. received reduced intensity conditioning with melphalan 140 mg/m2. 48% of patients completed the ASCT without requiring hospitalization and 52% (n = 26) of patients required hospitalization with a median duration of hospital admission of 9 days (IQR 5–13). Reasons for hospitalization included fever or infection (32%), cardiac arrhythmia (36%), and dehydration (32%). Overall response rate was 100% with a complete response seen in 57% of patients. Median overall survival and progression free survival for the cohort were 82 months and 33 months, respectively. One patient died within 100 days of transplant representing a 2% 100-day mortality rate. ASCT is safe and efficacious in carefully selected MM patients aged 75 or above and we believe that age should not be an exclusion factor for ASCT in MM.

Original languageEnglish (US)
Pages (from-to)1144-1150
Number of pages7
JournalBone Marrow Transplantation
Issue number5
StatePublished - May 2021

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents'. Together they form a unique fingerprint.

Cite this